GlobeNewswire

XBiotech Announces Plan to Launch Randomized Phase 2b Study of Bermekimab in Hidradenitis Suppurativa

Del

AUSTIN, Texas, May 23, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced plans to advance its dermatology program for its true human antibody bermekimab with the launch of a randomized, double-blind, placebo controlled, Phase 2b clinical study in patients with moderate to severe Hidradenitis Suppurativa (HS). This Phase 2b study will evaluate safety and efficacy of bermekimab at different subcutaneous doses compared with placebo. The study will further evaluate efficacy of bermekimab in HS and guide dosing strategies for the anticipated Phase 3 registration study. The Company expects the first patient to be enrolled during the third quarter of 2019.

The Phase 2b study follows two previous successful clinical studies of bermekimab to treat HS.  XBiotech recently evaluated bermekimab in a phase 2 study involving two groups of patients with HS: those who had no prior treatment with biologics; and those who had failed the only approved biological therapy to treat HS. The study, which was conducted at eleven research centers across the U.S. showed bermekimab was similarly effective in HS patients regardless of prior treatment with the current approved therapy.

Results of the study demonstrated that weekly treatment with bermekimab was associated with statistically significant improvement in HS, as measured by the FDA-sanctioned Hidradenitis Suppurativa Clinical Response score (HiSCR). In the study, 61% of patients with no prior biological therapy achieved positive HiSCR at 12 weeks, while 63% of patients who had failed previous biological therapy also achieved a positive HiSCR. HS is associated with severe pain and thus pain was a key measure in the study. At the study’s endpoint, patients with no prior biological therapy had a 64% reduction in pain compared with baseline, while those who had previously failed anti-TNF therapy had a 54% reduction in pain (for the only approved therapy for HS (Humira), only 43% of patients achieved HiSCR in its Phase III study that did not allow antibiotics; and there was no significant reduction in pain for Humira treated patients in the Phase 3 study).

XBiotech’s President & CEO, John Simard, commented, “We are extremely excited about the potential of bermekimab to treat inflammatory skin disease. We are eager to advance this program in HS and to ultimately deliver a new treatment to patients suffering from this devastating disease.”

Hidradenitis Suppurativa (HS) is a chronic, inflammatory skin disorder affecting areas rich in apocrine glands. Nodules appear in the affected areas and progressively become swollen with spontaneous rupture and release of pus. This process occurs repeatedly leading to formation of deep sinus tracts and painful dermal abscesses. Pain is a paramount condition in patients suffering from HS, as this chronic inflammation and accompanying pain account for the fact that HS is ranked first among skin disorders in terms of adversely affecting quality of life. The global prevalence of HS is estimated at up to 4% of the population.

About True Human™ Therapeutic Antibodies
XBiotech’s True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.

About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact
Ashley Otero
aotero@xbiotech.com
512-386-2930

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

FIDO Alliance Announces New Identity Verification and IoT Initiatives to Expand the Reach and Impact of FIDO Authentication26.6.2019 16:30:00 CESTPressemelding

New working groups formed to secure adjacent technologies that are critical for end-to-end identity lifecycle management WASHINGTON, June 26, 2019 (GLOBE NEWSWIRE) -- IDENTIVERSE -- The FIDO Alliance today announced two new standards and certification initiatives in identity verification and the Internet of Things (IoT). These initiatives build upon the Alliance’s ongoing focus on driving the efficacy and market adoption of FIDO Authentication by addressing adjacent technology areas that leave security vulnerabilities on the web. Specifically, the Alliance aims to strengthen identity verification assurance to support better account recovery, and automate secure device onboarding to remove password use from IoT. The Alliance has formed two new working groups: the Identity Verification and Binding Working Group (IDWG) and the IoT Technical Working Group (IoT TWG) to establish guidelines and certification criteria in these areas. The FIDO Alliance will continue to focus on development and

Enablon’s Sustainable Performance Forum (SPF) Focuses on the Future of EHS, Risk and Sustainability26.6.2019 16:21:00 CESTPressemelding

New Risk, Safety and Sustainability innovations in mobility, IOT integrations, and artificial intelligence (AI) used live on stage with early-adopter customers CHICAGO and PARIS, June 26, 2019 (GLOBE NEWSWIRE) -- Wolters Kluwer’s Enablon, a global leader in EHS, Risk and Sustainability Management software, announced at SPF 2019 new innovations executing on its Industry 4.0 Connected Enterprise strategy. The global SPF conference series leads the industry with more than 1,000 attendees from over 35 countries, 20 industry user groups, 120 expert sessions and 80 customer and partner presentations. At SPF Americas and SPF EMEA, Enablon announced new solutions across its suite of applications in Health & Safety Management, Governance, Risk & Compliance, Environmental Management & Sustainability, Process Safety & Control of Work, and Product Stewardship & Quality. The conferences focused on execution against Enablon’s Industry 4.0 Connected Enterprise vision, announcing new platform innovati

Kim Crawford Introduces New “Make It Amazing” Marketing Campaign26.6.2019 16:00:00 CESTPressemelding

Most Advertised Wine Brand Celebrates Consumer Loyalty and Self-Confidence MARLBOROUGH, New Zealand, June 26, 2019 (GLOBE NEWSWIRE) -- Kim Crawford, the number-one Sauvignon Blanci and leading New Zealand wine brandii in the U.S., announces the launch of its new national marketing campaign. “Make It Amazing” celebrates the confidence Kim Crawford gives consumers by overdelivering on quality, taste and value; and brings consumers’ strong brand loyalty to life. This is Kim Crawford’s first marketing campaign since becoming the most advertised wine brand in 2018iii and is supported by a 360-degree integrated marketing plan including TV and digital advertising, social media content, dynamic displays at retail, strategic partnerships, consumer sampling, and experiential programming. Kim Crawford’s new “Make It Amazing” campaign brings the brand’s confident and contemporary voice to life, showcasing a diverse cast of women who embody Kim Crawford’s positive, inclusive, and effortlessly dynam

XBiotech Wins “Commercial Real Estate Award for Industrial Development” for its Headquarters in Austin, Texas26.6.2019 14:30:00 CESTPressemelding

AUSTIN, Texas, June 26, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that it is the recipient of the first place 2019 Commercial Real Estate Award for Industrial Development, chosen by the Austin Business Journal. XBiotech USA Inc. received the award for its integrated R&D, administrative, and manufacturing facility located just 15 minutes from downtown Austin. XBiotech began construction of its state-of-the-art facility in 2015 as part of a master plan to build its worldwide operations headquarters. The Austin Business Journal reported, “a ‘green living’ concept served as the guiding vision of the Southeast Austin campus of biosciences company XBiotech USA Inc. The 40,000-square-foot facility was built on 48 acres of dense terrain including creeks, dense vegetations…and a 100-year flood plain running across the south end of the site.” Austin's Best New Buildings: XBiotech Named as Winner in 2019 Commercial Real Estate Awards The acclaimed “open air” facility i

Abeona Therapeutics Appoints Dr. Victor Paulus Senior Vice President of Regulatory Affairs26.6.2019 14:00:00 CESTPressemelding

NEW YORK and CLEVELAND, June 26, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Victor Paulus, Ph.D. as Senior Vice President, Regulatory Affairs. The Company also announced the appointment of Jodie Gillon, M.P.H. as Vice President of Patient Advocacy and Clinical Affairs. Both Dr. Paulus and Ms. Gillon are reporting to Chief Executive Officer João Siffert, M.D. “The addition of these seasoned industry leaders will strengthen our relationships with key stakeholders toward the successful development of our therapies,” said Dr. Siffert. “Victor will lead us through the evolving regulatory landscape in close collaboration with the development, CMC, and quality teams as we close in on near-term milestones and prepare to bring new gene and cell therapies to patients. He has a proven track record of shaping preclinical and clinical regulatory strategies and securing product approvals.” “

Bombardier wins ten-year APM operations and maintenance contract in California26.6.2019 11:10:00 CESTPressemelding

New agreement continues long-standing relationship with San Francisco International Airport Latest contract highlights Bombardier’s position as industry-leading services provider for automated transit systems BERLIN, June 26, 2019 (GLOBE NEWSWIRE) -- Note to editors: To view the photo associated with this press release, please visit the following link: https://www.globenewswire.com/NewsRoom/AttachmentNg/626ee106-c9c7-46df-9bf6-f7544a7a401a Mobility technology leader Bombardier Transportation announced today that it has signed a new contract with the City and County of San Francisco to provide ten years of operations and maintenance services for the BOMBARDIER INNOVIA APM 100 automated people mover (APM) system at San Francisco International Airport (SFO). The contract is valued at $220 million US (193 million euro) and includes an option for an additional five years. “With this new contract, we will continue to provide San Francisco International Airport with the operations and mainten